GPP
NBIX icon

Great Point Partners’s Neurocrine Biosciences NBIX Stock Holding History

Great Point Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-46,200
Closed -$1.03M – 37
2014
Q4 		$1.03M Buy
+46,200
New +$875K 0.5% 23

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Great Point Partners's NBIX Position: Q3 2022 in Review

Great Point Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 75,000 shares — an estimated $7.31M sold.

Great Point Partners first reported a position in NBIX in Q1 2014 and held it in 13 quarters. The position peaked at $33.2M in Q1 2018. 467 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Great Point Partners reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
  • Great Point Partners sold 75,000 Neurocrine Biosciences shares in Q3 2022, an estimated $7.31M.
  • Great Point Partners first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 13 quarters.
  • Great Point Partners's Neurocrine Biosciences position peaked at $33.2M in Q1 2018.
  • 467 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Great Point Partners's 13F filing for Q3 2022, filed 14 Nov 2022.